Clinical Trials Directory

Trials / Completed

CompletedNCT04495075

Neuromuscular Control in Individuals Following ACL-Reconstruction

The Use of Visuomotor Therapy to Modulate Corticospinal Excitability in Patients Following ACL-Reconstruction

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
University of Virginia · Academic / Other
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the neurophysiological contributors to muscle function following ACL Reconstruction and the influence of motor control biofeedback exercise on measures of muscle function. The research team hypothesizes that the application of motor biofeedback will increase cortical excitability of the quadriceps compared to the passive movement of the knee. This is a single session cross-over intervention study with a 1-week washout period between treatment arms.

Detailed description

1. Pre-treatment neuromuscular assessment Cortical Active Motor Threshed We will measure motor evoked potentials with the use of a Transcranial magnetic stimulator (MagStim model 200, Magstim Co., Ltd., Wales, UK). The MagStim has FDA 510K Clearance for stimulation of peripheral nerves. * The participant will be asked to sit in the dynamometer (Biodex, System 3) in knee extension at 90 degrees of knee flexion. * EMG electrodes will be placed on the distal quadriceps o Local shaving, debridement, and cleaning will be done prior if necessary * A non-latex swim cap will be placed on the participants head for investigator's measurements * Briefly, a magnetic field with a maximum value of 2.2 Tesla will be introduced to the scalp at a location in the pre-motor cortex that corresponds to the quadriceps. Single pulse stimulations will be delivered with no less than 10 seconds between stimulations (maximum = 0.1 Hz). * When the magnetic field is received at the premotor cortex at the appropriate area, a motor signal is sent to the quadriceps. We will record this signal with surface EMG electrodes that are on the quadriceps. * The participant will be asked to extend their leg to match a force equivalent to 5% MVIC. Feedback will be provided to the participant to provide such force. * Stimulation of the TMS will happen once every ten seconds until the Active Motor Threshold was found by the investigator. * The motor evoked potential measured by the quadriceps will be recorded at 80%, 90%, 100%, 110%, 120%, 130%, 140%, and 150% of the patients Active motor threshold. 2. Patient randomization \- The patient is then randomized to 1 of 2 treatment arms. 1) Visuomotor Therapy or 2) Passive Motion 3. Perform Randomized Treatment Visuomotor Therapy * The participant will sit in the Biodex chair with the tested limb secured in the dynamometer * The participant will receive live real-time biofeedback of their knee force output (no more than 30% of maximum force) * The participant will aim to match their force output to a target threshold presented on the screen. * The participant will complete 10 60-second trials of this exercise with a 30 second rest between each trial. OR Passive Motion * The participant will sit in the Biodex chair with the tested limb secured in the dynamometer * The dynamometer will passively move the patients lower limb between 80 to 120 degrees of knee flexion * The participant will be asked to relax for the duration of testing - The participant will complete 10 60-second trials of this exercise with a 30 second rest between each trial. 4. Reassess Neuromuscular outcome (Step 1) 5. 1-week washout period 6. Repeat Steps 1 through 4 but the patient receives the cross-over arm intervention

Conditions

Interventions

TypeNameDescription
OTHERVisuomotor TherapyThe use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed "visuomotor therapy". Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback.
OTHERPassive MotionThe knee is passively moved through a range of motion.

Timeline

Start date
2019-03-01
Primary completion
2020-03-01
Completion
2020-03-01
First posted
2020-07-31
Last updated
2020-07-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04495075. Inclusion in this directory is not an endorsement.